These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Radiotherapy for moderate-to-severe Graves' ophthalmopathy: improved outcomes with early treatment. Alpert TE; Alpert SG; Bersani TA; Hahn SS; Bogart JA; Chung CT Cancer J; 2003; 9(6):472-5. PubMed ID: 14740976 [TBL] [Abstract][Full Text] [Related]
48. Cyclophosphamide in the management of advanced Graves' ophthalmopathy. A preliminary report. Bigos ST; Nisula BC; Daniels GH; Eastman RC; Johnston HH; Kohler PO Ann Intern Med; 1979 Jun; 90(6):921-3. PubMed ID: 582090 [TBL] [Abstract][Full Text] [Related]
49. Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine. Barth A; Probst P; Bürgi H J Endocrinol Invest; 1991 Mar; 14(3):209-12. PubMed ID: 2071823 [TBL] [Abstract][Full Text] [Related]
51. Prevalence of increased intraocular pressure in Graves' disease--evidence of frequent subclinical ophthalmopathy. Gamblin GT; Harper DG; Galentine P; Buck DR; Chernow B; Eil C N Engl J Med; 1983 Feb; 308(8):420-4. PubMed ID: 6687400 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy. Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116 [TBL] [Abstract][Full Text] [Related]
53. Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves' ophthalmopathy. Jankauskiene J; Imbrasiene D Medicina (Kaunas); 2006; 42(11):900-3. PubMed ID: 17172791 [TBL] [Abstract][Full Text] [Related]
54. Natural history of graves' orbitopathy after treatment. Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471 [TBL] [Abstract][Full Text] [Related]
55. Ocular myasthenia gravis associated with euthyroid ophthalmopathy. Kusuhara T; Nakajima M; Imamura A Muscle Nerve; 2003 Dec; 28(6):764-6. PubMed ID: 14639594 [TBL] [Abstract][Full Text] [Related]
56. Development of Graves' ophthalmopathy and uveitis after radioiodine therapy for Graves' disease in a patient with HTLV-I associated myelopathy (HAM). Ozawa Y; Migita M; Watanabe T; Okuda I; Takeshita A; Takagi A; Shishiba Y Intern Med; 1994 Sep; 33(9):564-8. PubMed ID: 8000111 [TBL] [Abstract][Full Text] [Related]
57. Diagnostic criteria for Graves' ophthalmopathy. Bartley GB; Gorman CA Am J Ophthalmol; 1995 Jun; 119(6):792-5. PubMed ID: 7785696 [TBL] [Abstract][Full Text] [Related]
58. Radiotherapy of severe ophthalmic Graves' disease. van Ouwerkerk BM; Wijngaarde R; Hennemann G; van Andel JG; Krenning EP J Endocrinol Invest; 1985 Jun; 8(3):241-7. PubMed ID: 3839805 [TBL] [Abstract][Full Text] [Related]
59. Predictors of response to transantral orbital decompression in severe Graves' ophthalmopathy. Fatourechi V; Bergstralh EJ; Garrity JA; Bartley GB; Beatty CW; Offord KP; Gorman CA Mayo Clin Proc; 1994 Sep; 69(9):841-8. PubMed ID: 8065185 [TBL] [Abstract][Full Text] [Related]
60. Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy. Snijders-Keilholz A; De Keizer RJ; Goslings BM; Van Dam EW; Jansen JT; Broerse JJ Radiother Oncol; 1996 Jan; 38(1):69-71. PubMed ID: 8850428 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]